Zynga and StarLark Celebrate Golf Rival’s Fourth Anniversary
Today, StarLark, a subsidiary of Zynga Inc., announced it is celebrating the fourth anniversary of its popular fantasy-themed mobile golf game, Golf Rival, with multiple upcoming in-game events for players. To celebrate the title’s exciting growth, StarLark is sharing important milestones from the past four years as it looks to the future.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005196/en/
4 Year Anniversary (Graphic: Business Wire)
Four-year Anniversary Milestones
Golf Rival provides mobile golf enthusiasts around the world with adrenaline-packed player vs. player (PvP) competition filled with over-the-top moments like long-distance dunk shots and trick shots. Since its launch in 2018, the game has achieved the following milestones:
- Over 30 Million Game Downloads to date: And still growing!
- 5 Million Matches in One Day: A new landmark achieved in 2021
- Designed Over 250 Gorgeous Courses: Each course features spectacular scenery and fun shot strategies set over 26 themed locations across the globe
- 250+ Special Balls: Special balls give players another layer of strategy for various course conditions
- Ongoing Live Events: Fresh content keeps players engaged with over 150 Challenges, 125 Tournaments and 35 Kingdom seasons shared to date
- Over 17 Million Holes-in-One: Giving players millions of reasons to celebrate
“We believe Golf Rival has hit a hole-in-one with players because it appeals to both golf fans and casual gamers with a competitive, yet fantasy-driven golf experience,” said Henry You, StarLark Founder and General Manager. “We want to thank our players for the success we have achieved over the past four years and look forward to adding even more fun to the game through dynamic new content that our team is creating.”
Anniversary in-game events
A Golf Rival anniversary event is held each year at the ancient Isle of Goff, a fictional island paradise in the Golf Rival world where top competitors come to play. This spring, players will compete in two events held in an area of the island previously hidden by clouds – the majestic new Cloud Sea Golf Course that overlooks the ocean.
- Sky Walker Challenge: a 12-round PvP challenge on the Cloud Sea course that will run over two weekends (Mar 25-28 and Apr 2-4, 2022). Players that complete the challenge will be rewarded with ultimate chest prizes that contain a variety of coins, gems, club cards, golf balls and legendary clubs.
- Cloud Nine Tournament: For players who prefer a solo challenge, Cloud Sea will also be open for an 18-hole standalone event (Mar 26-28, Mar 28-30, and Apr 1-4, 2022). In the contest, golfers can try to master the course to achieve new personal best records and earn special prizes.
“I never fail to be amazed by the passion and dedication the Golf Rival team brings every day,” said Yaron Leyvand, Executive Vice President, Games at Zynga. “They continuously engage mobile golfers worldwide by creating over-the-top fantasy golf experiences that consistently raise the quality bar and surprise and delight our players with each new content drop.”
For additional information on this and future in-game events, please visit Golf Rival on Facebook.
Editor’s note:
For key art and broadcast assets, click here.
About Zynga Inc.
Zynga is a global leader in interactive entertainment with a mission to connect the world through games. With massive global reach in more than 175 countries and regions, Zynga has a diverse portfolio of popular game franchises that have been downloaded more than four billion times on mobile including CSR Racing™, Empires & Puzzles™, FarmVille™, Golf Rival™, Hair Challenge, Harry Potter: Puzzles & Spells™, High Heels!, Merge Dragons!™, Merge Magic!™, Toon Blast™, Toy Blast™, Words With Friends™ and Zynga Poker™. With Chartboost, a leading mobile advertising and monetization platform, Zynga is an industry-leading next-generation platform with the ability to optimize programmatic advertising and yields at scale. Founded in 2007, Zynga is headquartered in California with locations in North America, Europe and Asia. For more information, visit www.zynga.com or follow Zynga on Twitter, Instagram, Facebook or the Zynga blog.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005196/en/
Contact information
Zynga Media Contact:
Jenny Taylor
jetaylor@zynga.com
(310) 849-0648
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom